Literature DB >> 20496262

Development of therapeutic agents for older patients with acute myelogenous leukemia.

Christopher S Hourigan1, Judith E Karp.   

Abstract

Acute myelogenous leukemia (AML) is a disease more common in older patients than in the young. It is increasingly recognized that conventional cytotoxic chemotherapies used in children and young adults may not be appropriate in older adults because of diverse host- and disease-biology factors. This review highlights some of the most promising new treatment options that are being evaluated for older patients with AML. These options include CPX-351 (Celator Pharmaceuticals Inc), a unique liposomal formulation of a fixed ratio of cytarabine and daunorubicin; timed sequential therapy with the CDK inhibitor alvocidib (flavopiridol; sanofi-aventis/NCI); the second-generation purine nucleoside analog clofarabine; the farnesyltransferase inhibitor tipifarnib (Johnson & Johnson Pharmaceutical Research and Development LLC); and the DNA methyltransferase inhibitors decitabine and azacitidine.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20496262      PMCID： PMC4699173     

Source DB:  PubMed          Journal:  Curr Opin Investig Drugs        ISSN： 1472-4472


  40 in total

1.  Phase II study of clofarabine monotherapy in previously untreated older adults with acute myeloid leukemia and unfavorable prognostic factors.

Authors:  Hagop M Kantarjian; Harry P Erba; David Claxton; Martha Arellano; Roger M Lyons; Tibor Kovascovics; Janice Gabrilove; Michael Craig; Dan Douer; Michael Maris; Stephen Petersdorf; Paul J Shami; Andrew M Yeager; Stephen Eckert; Rekha Abichandani; Stefan Faderl
Journal:  J Clin Oncol       Date:  2009-12-21       Impact factor: 44.544

2.  Multicenter, phase II study of decitabine for the first-line treatment of older patients with acute myeloid leukemia.

Authors:  Amanda F Cashen; Gary J Schiller; Margaret R O'Donnell; John F DiPersio
Journal:  J Clin Oncol       Date:  2009-12-21       Impact factor: 44.544

3.  Age and acute myeloid leukemia.

Authors:  Frederick R Appelbaum; Holly Gundacker; David R Head; Marilyn L Slovak; Cheryl L Willman; John E Godwin; Jeanne E Anderson; Stephen H Petersdorf
Journal:  Blood       Date:  2006-02-02       Impact factor: 22.113

4.  A phase 2 study of the farnesyltransferase inhibitor tipifarnib in poor-risk and elderly patients with previously untreated acute myelogenous leukemia.

Authors:  Jeffrey E Lancet; Ivana Gojo; Jason Gotlib; Eric J Feldman; Jacqueline Greer; Jane L Liesveld; Laura M Bruzek; Lawrence Morris; Youn Park; Alex A Adjei; Scott H Kaufmann; Elizabeth Garrett-Mayer; Peter L Greenberg; John J Wright; Judith E Karp
Journal:  Blood       Date:  2006-11-02       Impact factor: 22.113

5.  High-dose daunorubicin in older patients with acute myeloid leukemia.

Authors:  Bob Löwenberg; Gert J Ossenkoppele; Wim van Putten; Harry C Schouten; Carlos Graux; Augustin Ferrant; Pieter Sonneveld; Johan Maertens; Mojca Jongen-Lavrencic; Marie von Lilienfeld-Toal; Bart J Biemond; Edo Vellenga; Marinus van Marwijk Kooy; Leo F Verdonck; Joachim Beck; Hartmut Döhner; Alois Gratwohl; Thomas Pabst; Gregor Verhoef
Journal:  N Engl J Med       Date:  2009-09-24       Impact factor: 91.245

6.  Clinical activity of sequential flavopiridol, cytosine arabinoside, and mitoxantrone for adults with newly diagnosed, poor-risk acute myelogenous leukemia.

Authors:  Judith E Karp; Amanda Blackford; B Douglas Smith; Katrina Alino; Amy Hatfield Seung; Javier Bolaños-Meade; Jacqueline M Greer; Hetty E Carraway; Steven D Gore; Richard J Jones; Mark J Levis; Michael A McDevitt; L Austin Doyle; John J Wright
Journal:  Leuk Res       Date:  2009-12-04       Impact factor: 3.156

7.  Active oral regimen for elderly adults with newly diagnosed acute myelogenous leukemia: a preclinical and phase 1 trial of the farnesyltransferase inhibitor tipifarnib (R115777, Zarnestra) combined with etoposide.

Authors:  Judith E Karp; Karen Flatten; Eric J Feldman; Jacqueline M Greer; David A Loegering; Rebecca M Ricklis; Lawrence E Morris; Ellen Ritchie; B Douglas Smith; Valerie Ironside; Timothy Talbott; Gail Roboz; Son B Le; Xue Wei Meng; Paula A Schneider; Nga T Dai; Alex A Adjei; Steven D Gore; Mark J Levis; John J Wright; Elizabeth Garrett-Mayer; Scott H Kaufmann
Journal:  Blood       Date:  2008-12-24       Impact factor: 22.113

8.  Age-specific differences in oncogenic pathway dysregulation and anthracycline sensitivity in patients with acute myeloid leukemia.

Authors:  Arati V Rao; Peter J M Valk; Klaus H Metzeler; Chaitanya R Acharya; Sascha A Tuchman; Marvaretta M Stevenson; David A Rizzieri; Ruud Delwel; Christian Buske; Stefan K Bohlander; Anil Potti; Bob Löwenberg
Journal:  J Clin Oncol       Date:  2009-10-26       Impact factor: 44.544

9.  Risk factors and decision criteria for intensive chemotherapy in older patients with acute myeloid leukemia.

Authors:  Jean-Valère Malfuson; Anne Etienne; Pascal Turlure; Thierry de Revel; Xavier Thomas; Nathalie Contentin; Christine Terré; Sophie Rigaudeau; Dominique Bordessoule; Norbert Vey; Claude Gardin; Hervé Dombret
Journal:  Haematologica       Date:  2008-10-06       Impact factor: 9.941

10.  Phase 2 clinical and pharmacologic study of clofarabine in patients with refractory or relapsed acute leukemia.

Authors:  Hagop Kantarjian; Varsha Gandhi; Jorge Cortes; Srdan Verstovsek; Min Du; Guillermo Garcia-Manero; Francis Giles; Stefan Faderl; Susan O'Brien; Sima Jeha; Jan Davis; Zeev Shaked; Adam Craig; Michael Keating; William Plunkett; Emil J Freireich
Journal:  Blood       Date:  2003-06-05       Impact factor: 22.113
View more
  8 in total

1.  Multi-institutional phase 2 clinical and pharmacogenomic trial of tipifarnib plus etoposide for elderly adults with newly diagnosed acute myelogenous leukemia.

Authors:  Judith E Karp; Tatiana I Vener; Mitch Raponi; Ellen K Ritchie; B Douglas Smith; Steven D Gore; Lawrence E Morris; Eric J Feldman; Jacqueline M Greer; Sami Malek; Hetty E Carraway; Valerie Ironside; Steven Galkin; Mark J Levis; Michael A McDevitt; Gail R Roboz; Christopher D Gocke; Carlo Derecho; John Palma; Yixin Wang; Scott H Kaufmann; John J Wright; Elizabeth Garret-Mayer
Journal:  Blood       Date:  2011-10-14       Impact factor: 22.113

Review 2.  Minimal residual disease in acute myeloid leukaemia.

Authors:  Christopher S Hourigan; Judith E Karp
Journal:  Nat Rev Clin Oncol       Date:  2013-06-25       Impact factor: 66.675

3.  Treatment of elderly acute myeloid leukemia patients.

Authors:  Gabriela Motyckova; Richard M Stone
Journal:  Curr Treat Options Oncol       Date:  2011-12

Review 4.  Immunological effects of hypomethylating agents.

Authors:  Katherine E Lindblad; Meghali Goswami; Christopher S Hourigan; Karolyn A Oetjen
Journal:  Expert Rev Hematol       Date:  2017-07-03       Impact factor: 2.929

5.  Materials innovation for co-delivery of diverse therapeutic cargos.

Authors:  Megan E Godsey; Smruthi Suryaprakash; Kam W Leong
Journal:  RSC Adv       Date:  2013-12-21       Impact factor: 3.361

6.  American Society of Hematology 2020 guidelines for treating newly diagnosed acute myeloid leukemia in older adults.

Authors:  Mikkael A Sekeres; Gordon Guyatt; Gregory Abel; Shabbir Alibhai; Jessica K Altman; Rena Buckstein; Hannah Choe; Pinkal Desai; Harry Erba; Christopher S Hourigan; Thomas W LeBlanc; Mark Litzow; Janet MacEachern; Laura C Michaelis; Sudipto Mukherjee; Kristen O'Dwyer; Ashley Rosko; Richard Stone; Arnav Agarwal; L E Colunga-Lozano; Yaping Chang; QiuKui Hao; Romina Brignardello-Petersen
Journal:  Blood Adv       Date:  2020-08-11

7.  Adult Acute Myeloid Leukemia Long-term Survivors.

Authors:  M Jennifer Cheng; Christopher S Hourigan; Thomas J Smith
Journal:  J Leuk (Los Angel)       Date:  2014-04-10

8.  Current Approaches in the Treatment of Relapsed and Refractory Acute Myeloid Leukemia.

Authors:  Nestor R Ramos; Clifton C Mo; Judith E Karp; Christopher S Hourigan
Journal:  J Clin Med       Date:  2015-04       Impact factor: 4.241
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.